Whalesbook
Toh bhai, jab se Umang Vohra, jo pehle Cipla ke CEO the, Cohance Lifesciences mein Executive Chairman aur Group CEO bane hain (May 2026 se effective), tab se stock mein toofani tezi aa gayi hai. Monday ko ye 20% tak badh gaya aur upper circuit hit kar gaya. Majority owner, Advent International, ko ummeed hai ki Vohra ji ki experience company ko growth ki taraf le jayegi aur operations bhi sudharegi.
Vohra ka naam bada hai, unhone Cipla ko ek alag level par pohanchaaya hai. Ab Cohance Lifesciences bhi CDMO sector mein top player banna chahti hai. Yeh sector, jo complex chemistry, APIs, aur advanced therapies par focus karta hai, achhi growth dikhata hai. Investors ko lagta hai Vohra global business badhayenge aur clients ke saath relationship strong karenge.
Lekin haan, sab kuch itna bhi easy nahi hai. Stock surge se pehle, Cohance ka P/E ratio lagbhag 43.55 tha. Competition bhi tagdi hai - Syngene International ka P/E 43-58 ke beech hai aur Laurus Labs ka toh 64-104 se bhi upar chala jata hai. Aur ek important baat, pichhle saal stock 70% tak gir gaya tha, matlab Vohra ko bahut kuch sudharna padega. CDMO market mein global competition, price pressure, aur tech upgrades ka constant challenge rehta hai. Plus, Cohance ki Nacharam facility ko February 2026 mein USFDA Warning Letter mila tha, jo ek bada risk hai. Technical indicators bhi mixed signals de rahe hain.
Toh abhi toh Vohra ji ki entry ne hope jaga di hai, par company ka future is baat par depend karta hai ki wo leadership ki vision ko actual kaam mein kaise badalte hain. Regulatory compliance maintain karna, competition se deal karna, aur growth targets poore karna sab important hoga. MarketsMojo ne toh already 'Sell' rating di hui hai, toh sabki nazar management ke execution par rahegi.